Photocure (PHO.OL) President and CEO Kjetil Hestdal discusses the company’s photodynamic technology harnessed in Hexvix and Allumera. Hexvix, branded as Cysview in the U.S., aids in cystoscopy procedures for bladder and colorectal cancers. Photocure already has a market penetration of 30% in the Nordic region, says Hestdal, and hopes to replicate that in the 230,000 procedures performed annually in the United States. He discusses the company’s dermatological technology Allumera and details research on Phase II acne treatment Visonac, which he says has shown good efficacy and comparable results to existing oral antibiotics, though without some of the negatives.
The conversation includes development expectations for 2013 and 2014 and partnership details for the company, as well as the company’s capital structure.